You have free access to this content

Cancer

Cover image for Cancer

1 August 2004

Volume 101, Issue 3

Pages 435–654

  1. Editorial

    1. Top of page
    2. Editorial
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Biochemotherapy for melanoma : Rational therapeutics in the search for weapons of melanoma destruction (pages 435–438)

      Kim A. Margolin

      Version of Record online: 28 JUN 2004 | DOI: 10.1002/cncr.20402

      Understanding of the mechanisms underlying the activity and limitations of biochemotherapy remains inadequate. The design of new regimens should based on emerging knowledge regarding molecular mechanisms of oncogenesis, cancer cell proliferation and survival, and control apoptosis.

      See also pages 596–603.

  2. Review Article

    1. Top of page
    2. Editorial
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma : A systematic review (pages 439–449)

      Steven R. Deitcher and Marcelo P. V. Gomes

      Version of Record online: 28 JUN 2004 | DOI: 10.1002/cncr.20347

      All hormonal agents used for breast carcinoma chemoprevention and adjuvant therapy increase the risk of venous thromboembolic events. Available data are insufficient to support any assumptions that newer hormonal agents are safer than tamoxifen in women with advanced breast carcinoma.

  3. Original Articles

    1. Top of page
    2. Editorial
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Breast cancer survivorship in a multiethnic sample : Challenges in recruitment and measurement (pages 450–465)

      Kimlin T. Ashing-Giwa, Geraldine V. Padilla, Judith S. Tejero and Jinsook Kim

      Version of Record online: 18 JUN 2004 | DOI: 10.1002/cncr.20370

      • original image
      • original image
      • original image
      • original image
      • original image

      The rate of participation among a diverse, population-based sample of breast cancer survivors was found to be influenced by ethnicity, age, and site of recruitment. Despite important recruitment and measurement challenges, this study obtained acceptable participation rates and good internal consistency of the measures. The results demonstrate the utility of a culturally responsive approach to health disparities research.

    2. You have free access to this content
      ‘Chemobrain’ in breast carcinoma? : A prologue (pages 466–475)

      Jeffrey S. Wefel, Renato Lenzi, Richard Theriault, Aman U. Buzdar, Scott Cruickshank and Christina A. Meyers

      Version of Record online: 21 JUN 2004 | DOI: 10.1002/cncr.20393

      • original image
      • original image
      • original image
      • original image

      Approximately 35% of women with breast carcinoma exhibited impaired cognitive function before receiving chemotherapy. The authors examined potential demographic, disease-related, and clinical factors associated with impaired cognitive function and discussed the implications for chemotherapy trial design.

    3. You have free access to this content
      The management of early breast carcinoma before and after the introduction of clinical practice guidelines (pages 476–485)

      Victoria White, Myee Pruden, Graham Giles, John Collins, Konrad Jamrozik, Graeme Inglis, John Boyages and David Hill

      Version of Record online: 21 JUN 2004 | DOI: 10.1002/cncr.20401

      Assessment of the management of early breast carcinoma before and after the introduction of clinical practice guidelines demonstrated that management practices became more in line with guideline recommendations.

    4. You have free access to this content
      Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node–negative breast carcinoma (pages 486–494)

      Peggy Manders, Vivianne C. G. Tjan-Heijnen, Paul N. Span, Nicolai Grebenchtchikov, Anneke Geurts-Moespot, Doorlène T. H. van Tienoven, Louk V. A. M. Beex and Fred C. G. J. Sweep

      Version of Record online: 18 JUN 2004 | DOI: 10.1002/cncr.20374

      • original image
      • original image
      • original image

      Urokinase-type plasminogen activator (uPA) and uPA inhibitor type 1 (PAI-1) have been proven to have prognostic value in patients with primary breast carcinoma in the absence of adjuvant systemic therapy. In the current study, the authors investigated whether the complex of uPA with PAI-1 is also associated with the natural course of breast carcinoma and found that tumor levels of this complex do in fact have prognostic value.

    5. You have free access to this content
      Mammographic screening: Patterns of use and estimated impact on breast carcinoma survival (pages 495–507)

      Karen Blanchard, James A. Colbert, Dhruv Puri, Joel Weissman, Beverly Moy, Daniel B. Kopans, Emily M. Kaine, Richard H. Moore, Elkan F. Halpern, Kevin S. Hughes, Kenneth K. Tanabe, Barbara L. Smith and James S. Michaelson

      Version of Record online: 21 JUN 2004 | DOI: 10.1002/cncr.20392

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Analysis of the pattern of screening utilization reveals a disappointingly low level of screening use, with potentially negative health consequences, among women of all racial, ethnic, socioeconomic, insurance, language, age, medical history, and previous screening-use categories. Improving the promptness of return to screening appears to have the potential to lead to considerable reductions in breast cancer death.

    6. You have free access to this content
      Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge (pages 508–517)

      Neslihan Cabioglu, Savitri Krishnamurthy, Henry M. Kuerer, Kelly K. Hunt, S. Eva Singletary, Funda Meric-Bernstam, Merrick I. Ross, Barry W. Feig, Frederick C. Ames and Gildy V. Babiera

      Version of Record online: 28 JUN 2004 | DOI: 10.1002/cncr.20394

      The authors assessed the feasibility of breast-conserving surgery (BCS) in 48 cases of breast carcinoma associated with nipple discharge. Patients in the study cohort presented primarily with early-stage breast carcinoma associated with ductal carcinoma in situ. Although occult nipple-areola complex involvement is not an uncommon finding in such patients, BCS can be performed safely if negative margins are achieved and if appropriate adjuvant radiotherapy or systemic therapy is administered.

    7. Gastrointestinal Tract
      You have free access to this content
      Adenocarcinoma of the small bowel : Presentation, prognostic factors, and outcome of 217 patients (pages 518–526)

      Bouthaina S. Dabaja, Dima Suki, Barbara Pro, Mark Bonnen and Jaffer Ajani

      Version of Record online: 22 JUN 2004 | DOI: 10.1002/cncr.20404

      • original image
      • original image
      • original image
      • original image
      • original image

      Cancer-directed surgery and lymph node involvement ratio were independent predictors of overall survival for patients with adenocarcinoma of the small bowels.

    8. Genitourinary Disease
      You have free access to this content
      Prostate needle biopsies : Multiple variables are predictive of final tumor volume in radical prostatectomy specimens (pages 527–532)

      Chistopher K. Poulos, Joanne K. Daggy and Liang Cheng

      Version of Record online: 18 JUN 2004 | DOI: 10.1002/cncr.20415

      • original image

      In the current study, the authors found that the highest percentage of adenocarcinoma in any biopsy site, the percentage of adenocarcinoma in the biopsy site with the highest Gleason score, the number of positive biopsy sites, the bilaterality of the tumor, and the percentage of biopsy sites positive for disease were useful preoperative predictors of tumor volume in radical prostatectomy specimens. Although these preoperative biopsy parameters were significant in linear regression models, none was sufficient as a single predictor of tumor volume.

    9. You have free access to this content
      Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951) (pages 533–540)

      Sophie D. Fosså, Gerald H. J. Mickisch, Pieter H. M. De Mulder, Simon Horenblas, Allan T. van Oosterom, Hein van Poppel, Martin Fey, Jelle J. Croles, Linda de Prijck and Martine Van Glabbeke

      Version of Record online: 18 JUN 2004 | DOI: 10.1002/cncr.20307

      • original image

      Based on the results from this randomized Phase II study, the survival-prolonging efficacy of the combination of interferon α with 13-cis retinoic acid should be assessed in a Phase III trial. Considerable interobserver variability of objective response evaluation warrants central review of claimed responses in patients with metastatic renal cell carcinoma.

    10. You have free access to this content
      Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy (pages 541–549)

      Tracey L. Krupski, Matthew R. Smith, Won Chan Lee, Chris L. Pashos, Jane Brandman, Qin Wang, Marc Botteman and Mark S. Litwin

      Version of Record online: 21 JUN 2004 | DOI: 10.1002/cncr.20388

      • original image

      Men with prostate carcinoma are at risk for adverse bone effects from both the disease and the treatment. The longitudinal data in the current study revealed that fractures are common in this patient population and appear to be linked to the duration of androgen deprivation therapy.

    11. You have free access to this content
      A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma (pages 550–557)

      Phyllis M. Windsor, Kathleen F. Nicol and Joan Potter

      Version of Record online: 22 JUN 2004 | DOI: 10.1002/cncr.20378

      • original image
      • original image
      • original image
      • original image
      • original image

      This prospective, randomized, controlled trial was performed to determine whether aerobic exercise would reduce the incidence of fatigue and prevent deterioration in physical functioning during radiotherapy for localized prostate carcinoma. The outcome measures were fatigue and distance walked before and after radiotherapy. Moderate-intensity walking appeared to produce a significant improvement in physical functioning and to prevent any significant increase in fatigue.

    12. Hematologic Malignancies
      You have free access to this content
      Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease (pages 558–566)

      Gordan Srkalovic, Marte G. Cameron, Lisa Rybicki, Steven R. Deitcher, Kandice Kattke-Marchant and Mohamad A. Hussein

      Version of Record online: 28 JUN 2004 | DOI: 10.1002/cncr.20405

      • original image
      • original image

      The authors reported that patients with monoclonal gammopathy of undetermined significance and multiple myeloma had an increased risk of venous thromboembolic disease. This risk needs to be studied further to understand and define the mechanism involved.

    13. You have free access to this content
      Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates : A historical cohort study (pages 567–577)

      Massimo Offidani, Laura Corvatta, Lara Malerba, Monica Marconi, Elisabetta Bichisecchi, Sara Cecchini, Esther Manso, Tiziana Principi, Stefano Gasparini and Pietro Leoni

      Version of Record online: 28 JUN 2004 | DOI: 10.1002/cncr.20406

      • original image
      • original image

      The authors proposed a risk model for predicting outcome in patients with hematologic malignancies who develop pulmonary infiltrates. Using parameters that were available at the onset of pulmonary infiltrates, univariate and multivariate analyses were performed to assess factors influencing outcome in a 110-patient historical cohort. The proposed model accurately predicted survival for patients with fever and pulmonary infiltrates and, once prospectively validated, may be used to select patients for trials involving novel diagnostic and therapeutic strategies.

    14. Hepatobiliary Disease
      You have free access to this content
      Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma (pages 578–586)

      Yehuda Z. Patt, Manal M. Hassan, Alvaro Aguayo, Ajay K. Nooka, Richard D. Lozano, Steven A. Curley, Jean-Nicolas Vauthey, Lee M. Ellis, Isac I. Schnirer, Robert A. Wolff, Chusilp Charnsangavej and Thomas D. Brown

      Version of Record online: 28 JUN 2004 | DOI: 10.1002/cncr.20368

      • original image

      The authors retrospectively assessed 63 patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were treated with oral capecitabine. The antitumor activity of single-agent capecitabine was most evident in patients with GBC, modest in patients with HCC, and poor in patients with CCA. With regard to toxicity, capecitabine was found to be relatively safe for all patients, including those with cirrhosis.

    15. Lung Disease
      You have free access to this content
      Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma : Using the LCSS-meso conceptual model for validation (pages 587–595)

      Patricia J. Hollen, Richard J. Gralla, Astra M. Liepa, James T. Symanowski and James J. Rusthoven

      Version of Record online: 28 JUN 2004 | DOI: 10.1002/cncr.20315

      • original image
      • original image
      • original image
      • original image

      The underpinning model for the Lung Cancer Symptom Scale (LCSS)-Meso, a quality-of-life measure for patients with malignant pleural mesothelioma, was tested with good results. Further support for the content validity and construct validity of the LCSS-Meso were obtained in the current study, which involved 495 patients.

    16. Melanoma
      You have free access to this content
      Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma (pages 596–603)

      Kevin B. Kim, Omar Eton, Mary Jo East, Cynthia Hodges, Nicholas E. Papadopoulos, Elizabeth A. Grimm and Agop Y. Bedikian

      Version of Record online: 22 JUN 2004 | DOI: 10.1002/cncr.20403

      Recent clinical studies using less dose-intensive biochemotherapy regimens reported decreased clinical efficacy in patients with advanced melanoma. The current pilot study demonstrated that dosing of concurrent biochemotherapy can be intensified cautiously in an inpatient ward.

      See also pages 435–8.

    17. Neuro-Oncology
      You have free access to this content
      Association between laminin-8 and glial tumor grade, recurrence, and patient survival (pages 604–612)

      Julia Y. Ljubimova, Manabu Fugita, Natalya M. Khazenzon, Asha Das, Brian B. Pikul, Daniel Newman, Kiyotoshi Sekiguchi, Lydia M. Sorokin, Takako Sasaki and Keith L. Black

      Version of Record online: 16 JUN 2004 | DOI: 10.1002/cncr.20397

      • original image
      • original image
      • original image

      Overexpression of laminin-8 in glioblastoma multiforme was found to be significantly associated with a shorter time to tumor recurrence (P < 0.0002) and a decreased patient survival time (P < 0.015). Laminin-8 may be used as a predictor of tumor recurrence and patient survival and as a potential molecular target for glioma therapy.

    18. You have free access to this content
      The prevalence of pituitary adenomas : A systematic review (pages 613–619)

      Shereen Ezzat, Sylvia L. Asa, William T. Couldwell, Charles E. Barr, William E. Dodge, Mary Lee Vance and Ian E. McCutcheon

      Version of Record online: 28 JUN 2004 | DOI: 10.1002/cncr.20412

      • original image

      Given the high frequency of pituitary adenomas and their potential for causing clinical pathologies, the findings of the current study suggested that early diagnosis and treatment of pituitary adenomas should have far-reaching benefits.

    19. You have free access to this content
      Brain metastases of malignant germ cell tumors in children and adolescents (pages 620–626)

      Sheri L. Spunt, Michael F. Walsh, Matthew J. Krasin, Kathleen J. Helton, Catherine A. Billups, Alvida M. Cain and Alberto S. Pappo

      Version of Record online: 22 JUN 2004 | DOI: 10.1002/cncr.20411

      • original image
      • original image

      Brain metastases are rare in pediatric germ cell tumors, and their incidence appears to be declining. In the current study, brain involvement occurred more frequently in pediatric patients with advanced-stage or extragonadal tumors, and in patients whose tumor contained a component of choriocarcinoma.

    20. Sarcoma
      You have free access to this content
      Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution (pages 627–634)

      Andrea Ferrari, Alessandro Gronchi, Michela Casanova, Cristina Meazza, Lorenza Gandola, Paola Collini, Laura Lozza, Rossella Bertulli, Patrizia Olmi and Paolo G. Casali

      Version of Record online: 28 JUN 2004 | DOI: 10.1002/cncr.20386

      • original image
      • original image

      The optimal treatment strategy for synovial sarcoma (SS) is subject to debate, and different strategies have been used for pediatric and adult patients. The authors retrospectively examined a large group of patients of all ages who were treated for SS at a single institution over a 30-year period. Although more convincing proof of the efficacy of adjuvant chemotherapy in the treatment of adult soft tissue sarcoma is required, the current study suggests that patients with high-risk SS be the first to be considered for this type of treatment.

    21. Discipline

      Pediatric Oncology
      You have free access to this content
      Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy (pages 635–641)

      Matteo Zignol, Marta Peracchi, Gloria Tridello, Marta Pillon, Federica Fregonese, Ruggiero D'Elia, Luigi Zanesco and Simone Cesaro

      Version of Record online: 18 JUN 2004 | DOI: 10.1002/cncr.20384

      Pediatric patients who have undergone chemotherapy are prone to lose the protective serum antibody titer acquired from previous vaccinations, with different rates of loss associated with different types of vaccination.

    22. You have free access to this content
      Hepatocellular carcinoma and liver tumors in South African children : A case for increased prevalence (pages 642–649)

      Samuel W. Moore, Alistair J. W. Millar, G. P. (Larry) Hadley, Gabriel Ionescu, Mariana Kruger, Janet Poole, David Stones, Linda Wainwright, Milind Chitnis and Glynn Wessels

      Version of Record online: 21 JUN 2004 | DOI: 10.1002/cncr.20398

      • original image

      A nationwide survey of liver tumors in South Africa showed that the incidence of hepatocellular carcinoma was lower in children compared with adults but was higher than in industrialized countries. This results in a lower ratio of hepatoblastoma to hepatocellular carcinoma in children.

  4. Correspondence

    1. Top of page
    2. Editorial
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
      Author reply (page 651)

      Alessandro Volpe, Michael A. S. Jewett and Andrew J. Evans

      Version of Record online: 22 JUN 2004 | DOI: 10.1002/cncr.20399

    3. You have free access to this content
      High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors (page 652)

      N. Julian H. Sturt, Robin K. S. Phillips and Susan K. Clark

      Version of Record online: 22 JUN 2004 | DOI: 10.1002/cncr.20416

    4. You have free access to this content
      Author reply (page 653)

      Anika Hansmann, Gabriela Moeslein and Tilman Vogel

      Version of Record online: 22 JUN 2004 | DOI: 10.1002/cncr.20419

    5. You have free access to this content
      Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site (page 654)

      Alberto Muñoz, José Ramón Barceló and Guillermo López-Vivanco

      Version of Record online: 9 JUN 2004 | DOI: 10.1002/cncr.20417

    6. You have free access to this content
      Author reply (page 654)

      Stéphane Culine

      Version of Record online: 9 JUN 2004 | DOI: 10.1002/cncr.20420

SEARCH

SEARCH BY CITATION